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Supraventricular tachycardia (SVT) is the most common arrhythmia in a neonate with an incidence of 1 in 200–250 [1]. In SVT, heart rate is usually >220 beats/min. 
Mechanisms causing SVT could be enhanced automaticity with 
triggered foci above the ventricles or enhanced conduction with 
the presence of reentrant circuits [2]. SVT caused by a reentrant 
mechanism is the most common form. The diagnosis of focal 
atrial tachycardia (FAT) was based on electrocardiogram (ECG). 
Ectopic atrial tachycardias are manifested as narrow complex 
tachycardias with an abnormal P wave preceding the QRS 
complex.
The following criteria have been used for diagnosing the 
FAT, (1) narrow complex tachycardia with visible P waves at a 
rate inappropriate for age and activity, (2) identical abnormal 
P wave morphology in the first and all subsequent tachycardia 
beats, (3) routine ECG atrial rate >150% of the predicted mean, 
(4) inverted and notched P wave in V1, (5) P wave axis in the 
horizontal plane <0°, and (6) P wave duration >90 ms in V1. In 
unifocal type of FAT, P wave morphology is similar in all leads 
(Fig. 1) and in multifocal type of FAT, P wave morphologies were 
different (Fig. 2). Spontaneous resolution is usually anticipated 
in FAT; therefore, it is better to consider medical therapy 
than ablation as it is associated with a number of side effects, 
particularly in children [3].
CASE REPORT
A 15-day-old male, term baby was admitted with complaints of 
excessive cry, lethargy, and decreased acceptance of feeds. He 
was born to a Primi mother by spontaneous vaginal delivery with 
birth weight of 2800 g and having no significant antenatal history 
reported. The baby mother noticed that the baby had sudden onset 
of restlessness since night and she also observed sweating over 
the forehead and palpitations when she was trying to breastfeed 
the baby. The baby cried immediately after birth and was given 
breastfeeds within ½ h after birth. The baby was on exclusive 
breastfeeds until now and received Bacille Calmette–Guerin, oral 
polio vaccine immediately after birth.
On thorough clinical examination, the baby looked ill and 
lethargic with no pallor, cyanosis, and jaundice. His heart rate 
was varying between 240/min and 320/min, respiratory rate was 
58/min, and capillary filling time was <3 s. His heart sounds were 
difficult to differentiate due to tachycardia. He had no significant 
audible murmur and lung base was clear. The baby had no signs 
of congestive cardiac failure; no hepatosplenomegaly and urine 
output was adequate.
Electrocardiography revealed narrow complex QRS waves 
with 2:1 AV block with abnormal P wave morphology suggestive 
of FAT (Fig. 1). Serum electrolytes were normal having sodium 
142 meq/L, potassium 5.2 meq/L, chloride 132 meq/L, and ionized 
calcium of 8 mg/dl. Blood urea was 13 mg/dl and serum creatine 
was 0.3 mg/dl. Septic screen was negative with C-reactive protein 
3 mg/dl, complete blood picture was normal with hemoglobin 
13 mg/dl, packed cell volume 45%, total leukocyte count 
8500 cells/mm3, and platelets 200,000/mm3. Chest X-ray was 
normal without any cardiomegaly. Echocardiography revealed 
features of the left ventricular dysfunction.
Initially, adenosine was administered followed by digoxin 
(10 mcg/kg/day) and beta-blocker (propranolol – 1 mg/kg/day); 
however, it failed to control heart rate. Then, amiodarone followed 
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by flecainide was given but we found no effect. Electric 
cardioversion was also tried without any response. As a last resort, 
the baby was started on ivabradine (0.05 mg/kg/day) before 
considering surgical ablation of focus and it ameliorated the 
atrial tachycardia and the heart rate was normalized. Ivabradine 
and propranolol were continued throughout his hospital stay 
and his heart rate was normalized which was evident in serial 
electrocardiograph. The baby was discharged after 2 days and 
was advised to continue ivabradine for 1 month. On follow-up, 
the baby was stable. A written consent was taken from the parents 
for administrating the drug and for publication.
DISCUSSION
The most common cause of SVT in neonates is usually 
reentrant mechanism. IV adenosine (0.1–0.3 mg/kg/dose) 
and rapid IV push are extremely effective in cardioversion of 
hemodynamically stable babies. Electrical cardioversion is useful 
in hemodynamically unstable babies. Holding a child upside 
down (with proper support) and placing a small bag or glove 
filled with ice over the entire face for 10–15 s is an effective 
maneuver (because it is a dive reflex, the majority of the face 
must be covered by ice). Calcium channel blockers should not 
be used for treating any type of SVT in neonate because neonatal 
myocardium is 20 times more sensitive than adults and might 
result in sudden death. In neonatal population for treating SVT, 
gagging, ocular pressure, and anal stimulation should be avoided.
In FAT, nodal blockade is not useful as pathology does not 
present in AV node. Adenosine administration usually blocks only 
AV nodal conduction that is why atrial arrhythmia will not be 
decreased by adenosine. Digoxin is also not generally effective 
as it also acts at AV node but may temporarily abate the rate. 
Sometimes, digoxin can cause AV dissociation by blocking AV 
node, further contributing to hemodynamic instability in addition 
to the rapid atrial rate. Direct current cardioversion may interrupt 
the arrhythmia but is most likely to reinitiate spontaneously after 
sometime.
FAT is usually diagnosed by ECG criteria as mentioned above; 
intermittent AV block (such as 2:1 conduction or Wenckebach 
pattern) could be seen sometimes. Due to aberrant ventricular 
conduction, sometimes, wide QRS may be seen similar to 
ventricular tachycardia (Ashman phenomenon). Focus is usually 
present at crista terminalis or ostia of the pulmonary veins [3]. 
Atrial ectopic tachycardia may be attempted with medications 
such as beta-blockers (propranolol), sodium channel blockers 
(flecainide), or Class III antiarrhythmic medications (sotalol and 
amiodarone). Catheter ablation of FAT in children aged <1.5 years 
and particularly in neonatal period is usually associated with more 
complications [4].
FAT occurs as a result of irritation of tissues during cardiac 
surgery, with the placement of intracardiac lines, application of 
sutures, or cutting cardiac tissue during surgery. In our case, there 
was no structural heart disease as evident in 2D echo, so the cause 
for the focus could be due to increased automaticity by a focus of 
cells through funny current channels. Funny current is a mixed 
sodium/potassium inward current activated on hyperpolarization 
in the diastolic range of voltages. Funny current channels are 
responsible for automaticity of myocytes in SA node.
Ivabradine selectively inhibits the funny current limited to the 
sinoatrial node in a dose-dependent manner without affecting any 
other cardiac ionic channels. Ivabradine blocks the intracellular 
aspect of the hyperpolarization-activated cyclic nucleotide-gated 
transmembrane channel, which is responsible for the transport of 
sodium (Na+) and potassium (K+) ions across the cell membrane, 
in the open state. It decreases the heart rate through deceleration 
of conduction through funny current channels. Ivabradine can 
be safe and potentially effective therapy for arrhythmias with 
enhanced automaticity. It is more effective in high heart rate 
conditions as it works on opened funny current channels.
The use of ivabradine in sinus tachycardia was noted in some 
case reports and small randomized trials. In a case series, Dieks et al. 
used ivabradine in five consecutive patients aged 10 days–3.5 years 
with a mean age of 8 weeks in junctional ectopic tachycardia (JET). 
The authors observed that four patients had satisfactory control 
of JET, whereas one patient had effective heart rate control with 
persistent slow JET with mean heart rate reduced by 31% compared 
to pre-ivabradine (p=0.03) [5]. Al-Ghamdi et al. treated resistant 
JET with oral ivabradine in a 3-year-old girl [6]. Bohora et al. 
reported a case of reversal of tachycardiomyopathy due to the left 
atrial tachycardia in a child by ivabradine [7]. Janson et al. reported 
diverse arrhythmia substrates, two cases of focal FAT of focal EAT 
in a structurally normal heart; one case of JET in a patient with a 
history of a neonatal mass involving the AV junction, associated with 
residual AV conduction disease; and one case of atrial tachycardia 
in a teenager following heart transplant. Ivabradine was safe in all 
patients, with no adverse events or side effects [8].
Figure 1: Abnormal P waves with similar morphology (indicates 
unifocal origin)
Figure 2: P wave with different morphologies multifocal atrial 
tachycardia
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The safety of oral ivabradine therapy in infants and children 
has been established in a cohort of children with dilated 
cardiomyopathy and stable heart failure [9]. In a randomized, 
double-blind, placebo-controlled trial, 116 children with dilated 
cardiomyopathy received either ivabradine (n=74) or placebo 
(n=42); the majority of patients in both the study groups were on 
beta-blocker, and many were also on digoxin. Adverse event rates 
were low overall and similar in both arms, there were no instances 
of AV block, atrial fibrillation, or other arrhythmias. Importantly, 
this trial also established that oral ivabradine has a similar 
pharmacokinetic and pharmacodynamic profile in children aged 
6 months–18 years to that seen in adults [10,11]. Ptaszynski et al. 
and Cappato et al. also used ivabradine successfully in pediatric 
age group to treat sinus tachycardia and JET [12,13].
FAT originating in the atrial appendages is more likely to 
respond to ivabradine than those arising from other atrial sites. 
Around 60%–80% of SVTs that present in the neonatal period 
resolve spontaneously within the 1st year of life. FAT in neonates 
resolve spontaneously in early months of life, long-term therapy 
is rarely necessary [14].
CONCLUSION
Ivabradine can be considered as a treatment option for FAT which 
is refractory to the other antiarrhythmic drugs. Ivabradine can be 
considered before resorting to invasive surgical ablation of the 
focus as ablation is associated with more complications.
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